Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [ Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, pr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in oncology Jg. 14; S. 1483953
Hauptverfasser:	Hansen, Aaron R., Probst, Stephan, Beauregard, Jean-Mathieu, Viglianti, Benjamin L., Michalski, Jeff M., Tagawa, Scott T., Sartor, Oliver, Tutrone, Ronald F., Oz, Orhan K., Courtney, Kevin D., Delpassand, Ebrahim S., Nordquist, Luke T., Osman, Medhat M., Chi, Kim N., Sparks, Richard, George, Noble, Hawley, Sara M., Wu, Wenting, Jensen, Jessica D., Fleshner, Neil E.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland Frontiers Media S.A 07.01.2025
Schlagworte:	castration resistant prostate cancer dosimetry Oncology PNT2002 PSMA radioligand therapy PSMA dosimetry PNT2002 castration resistant prostate cancer radioligand therapy
ISSN:	2234-943X, 2234-943X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!